April 28, 2008 - Osteotech Inc. said the FDA cleared its Plexur P Biocomposite for use in spinal applications as a bone void filler and as a bone graft extender.

Previously, Osteotech received FDA clearance for Plexur P for use in filling bony voids of the pelvis and extremities.

According to Osteotech, the Plexur P Biocomposite has been used by a variety of surgeons in tibial plateau fractures, tibial osteotomies and a variety of foot and ankle procedures, and can now be used in the spine. The Plexur P can be combined with the company�s Grafton DBM, local bone or the Kinesis BMAC cellular system. Plexur P is available as granules, cylinders, blocks, wedges and sheets. The Plexur uses bone tissue for procedure specific surgical applications in combination with a wide variety of polymers.

For more information: www.osteotech.com


Additional Content

News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
News | Prostate Cancer

Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...

Time November 11, 2025
arrow
News | Imaging Software Development

June 12, 2025 — GE HealthCare has announced the combination of GE HealthCare’s proprietary features and algorithms with ...

Time June 12, 2025
arrow
News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
Subscribe Now